Open Payments

Ascension St John Hospital

Type
Teaching hospital
Where
Detroit, MI
Medicare CCN
230165
Received
$1,666,846 in 182 records, 2022 ($31,060 general, $1,635,786 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2022General payment7$31,060
2022Research payment175$1,635,786

By company

CompanyRecordsAmountYears
PFIZER INC.33$779,0722022
JAZZ PHARMACEUTICALS INC.4$385,1252022
Medtronic, Inc.32$116,1842022
Genetesis, Inc.10$101,4302022
Genentech, Inc.21$63,8992022
Saranas, Inc.24$46,1232022
Eli Lilly and Company2$34,7002022
Penumbra, Inc.18$32,9652022
AngioDynamics, Inc.2$25,3332022
Abbott Laboratories11$23,2252022
Gilead Sciences, Inc.9$16,8902022
E.R. Squibb & Sons, L.L.C.1$14,4502022
Philips North America LLC3$7,4502022
Endologix LLC2$4,5172022
Boston Scientific Corporation2$4,0002022
Alexion Pharmaceuticals, Inc.1$2,8952022
Genentech USA, Inc.1$2,0002022
Celgene Corporation1$1,9102022
Impulse Dynamics (USA) Inc.1$1,7502022
Wilson Cook Medical Incorporated1$1,5002022
Octapharma USA, Inc.1$1,2002022
Cochlear Americas1$1652022
KARL STORZ Endoscopy-America1$612022

By nature of payment

NatureRecordsAmount
Research payment175$1,635,786
Long term medical supply or device loan3$25,394
Space rental or facility fees (teaching hospital only)2$3,500
Grant1$2,000
Debt forgiveness1$165

Records

DateCompanyAmountNatureFormProductStudyYear
2022-12-31AngioDynamics, Inc.$13,000Long term medical supply or device loanIn-kind items and servicesSolero Device, Oncology2022
2022-12-28PFIZER INC.$3,282Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-12-28Boston Scientific Corporation$2,000GrantCash or cash equivalentGENERAL - THERAPIES Device, THERAPIES2022
2022-12-23Genentech USA, Inc.$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentActivase Biological, Metabolism & Primary Care2022
2022-12-21PFIZER INC.$4,917Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-12-21PFIZER INC.$1,072Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-12-19Medtronic, Inc.$3,506Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2022
2022-12-19Medtronic, Inc.$3,506Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2022
2022-12-17PFIZER INC.$10,130Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-12-16PFIZER INC.$13,488Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-12-15Medtronic, Inc.$9,179Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2022
2022-12-15Medtronic, Inc.$9,179Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2022
2022-12-14PFIZER INC.$5,430Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-12-14Genetesis, Inc.$500Research paymentCash or cash equivalentMICRO ASJH2022
2022-12-10PFIZER INC.$32,049Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-12-07Genentech, Inc.$4,393Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-12-06Wilson Cook Medical Incorporated$1,500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2022
2022-12-03PFIZER INC.$25,768Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-11-30PFIZER INC.$458Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-11-29JAZZ PHARMACEUTICALS INC.$111,000Research paymentCash or cash equivalentVYXEOS Drug, HEMATOLOGY/ONCOLOGYA PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO T2022
2022-11-28Gilead Sciences, Inc.$993Research paymentCash or cash equivalentA Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib2022
2022-11-25Abbott Laboratories$3,000Research paymentCash or cash equivalent Device, Cardiac Rhythm ManagementSafety and Effectiveness Trial for the Nanostim Leadless Pacemaker2022
2022-11-23PFIZER INC.$42,346Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-11-18Penumbra, Inc.$1,125Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2022
2022-11-16PFIZER INC.$7,698Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-11-14Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2022
2022-11-14Medtronic, Inc.$500Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2022
2022-11-10PFIZER INC.$63,157Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-11-08PFIZER INC.$30,349Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-11-07Saranas, Inc.$2,208Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-11-07Boston Scientific Corporation$2,000Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTHI PEITHO2022
2022-11-04JAZZ PHARMACEUTICALS INC.$55,500Research paymentCash or cash equivalentVYXEOS Drug, HEMATOLOGY/ONCOLOGYA PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO T2022
2022-11-04Genetesis, Inc.$4,210Research paymentCash or cash equivalentACCMED2022
2022-11-03Saranas, Inc.$1,000Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-11-02PFIZER INC.$2,599Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-10-31Genetesis, Inc.$250Research paymentCash or cash equivalentMICRO ASJH2022
2022-10-28PFIZER INC.$15,174Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-10-27PFIZER INC.$7,395Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-10-26Eli Lilly and Company$17,950Research paymentCash or cash equivalentA PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS BENDAMUSTINE PLUS RITUXIMAB IN UNTREATED PATIE2022
2022-10-26Abbott Laboratories$2,630Research paymentCash or cash equivalent Device, Cardiac Rhythm ManagementSafety and Effectiveness Trial for the Nanostim Leadless Pacemaker2022
2022-10-20Saranas, Inc.$2,208Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-10-20Saranas, Inc.$1,173Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-10-18PFIZER INC.$5,058Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-10-14Genetesis, Inc.$5,000Research paymentCash or cash equivalentMICRO ASJH2022
2022-10-13Medtronic, Inc.$1,632Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2022
2022-10-13Medtronic, Inc.$1,632Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2022
2022-10-06PFIZER INC.$30,290Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPOLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUD2022
2022-10-06Penumbra, Inc.$2,717Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2022
2022-10-05Genentech, Inc.$155Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-10-03Medtronic, Inc.$7,104Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2022
2022-10-03Medtronic, Inc.$7,104Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2022
2022-09-30PFIZER INC.$19,520Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPOLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUD2022
2022-09-30PFIZER INC.$3,268Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-09-29Endologix LLC$2,567Research paymentCash or cash equivalentDetour II Study2022
2022-09-28Genentech, Inc.$2,068Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-09-26Genetesis, Inc.$8,740Research paymentCash or cash equivalentACCMED2022
2022-09-24PFIZER INC.$26,716Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-09-23Saranas, Inc.$2,208Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-09-23Saranas, Inc.$1,500Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-09-22PFIZER INC.$13,000Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED2022
2022-09-21Gilead Sciences, Inc.$1,906Research paymentCash or cash equivalentA Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib2022
2022-09-15Endologix LLC$1,950Research paymentCash or cash equivalentDetour II Study2022
2022-09-14Genentech, Inc.$2,600Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-09-14Genentech, Inc.$2,040Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-09-14Genentech, Inc.$2,000Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-09-14Genentech, Inc.$1,200Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-09-14Genentech, Inc.$938Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-09-13PFIZER INC.$7,660Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-09-09Medtronic, Inc.$525Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsOptimize Pro2022
2022-09-09Medtronic, Inc.$525Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsOptimize Pro2022
2022-09-01Penumbra, Inc.$4,995Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2022
2022-08-31Saranas, Inc.$1,173Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-08-31Saranas, Inc.$1,173Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-08-31Saranas, Inc.$1,173Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-08-31Saranas, Inc.$1,035Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-08-31Saranas, Inc.$1,035Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-08-31Saranas, Inc.$1,035Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-08-31Saranas, Inc.$1,000Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-08-31Saranas, Inc.$100Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-08-31Saranas, Inc.$100Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-08-25Abbott Laboratories$500Research paymentCash or cash equivalent Device, Cardiac Rhythm ManagementSafety and Effectiveness Trial for the Nanostim Leadless Pacemaker2022
2022-08-17Gilead Sciences, Inc.$683Research paymentCash or cash equivalentA Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib2022
2022-08-16PFIZER INC.$61,617Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-08-12JAZZ PHARMACEUTICALS INC.$83,250Research paymentCash or cash equivalentVYXEOS Drug, HEMATOLOGY/ONCOLOGYA PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO T2022
2022-08-03Genentech, Inc.$5,000Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-08-03Abbott Laboratories$3,330Research paymentCash or cash equivalent Device, Cardiac Rhythm ManagementSafety and Effectiveness Trial for the Nanostim Leadless Pacemaker2022
2022-08-03Genentech, Inc.$2,040Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-08-01Medtronic, Inc.$2,897Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2022
2022-08-01Medtronic, Inc.$2,897Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2022
2022-07-29PFIZER INC.$40,365Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-07-27Celgene Corporation$1,910Research paymentCash or cash equivalentRevlimid Drug, HematologyConnect MDS/AML - Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (A2022
2022-07-22Eli Lilly and Company$16,750Research paymentCash or cash equivalentSTUDY OF LOXO-305 VERSUS INVESTIGATOR'S CHOICE (IDELAR OR BR) IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LE2022
2022-07-20Genentech, Inc.$3,167Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-07-20Genentech, Inc.$1,947Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-07-20Genentech, Inc.$1,947Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-07-20Gilead Sciences, Inc.$1,259Research paymentCash or cash equivalentA Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib2022
2022-07-20Genentech, Inc.$62Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-07-18Gilead Sciences, Inc.$30Research paymentCash or cash equivalentA Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib2022
2022-07-15KARL STORZ Endoscopy-America$61Long term medical supply or device loanIn-kind items and servicesHOPKINS Device, CARDIO-VASCULAR SURGERY2022
2022-07-15Penumbra, Inc.$50Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2022
2022-07-12JAZZ PHARMACEUTICALS INC.$135,375Research paymentCash or cash equivalentVYXEOS Drug, HEMATOLOGY/ONCOLOGYA PHASE 3 RANDOMIZED TRIAL FOR PATIENTS WITH DE NOVO AML COMPARING STANDARD THERAPY INCLUDING GEMTUZUMAB OZOGAMICIN GO T2022
2022-07-12Medtronic, Inc.$7,165Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2022
2022-07-12Medtronic, Inc.$7,165Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2022
2022-07-08Saranas, Inc.$1,173Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-07-07Genetesis, Inc.$20,370Research paymentCash or cash equivalentACCMED2022
2022-07-05Penumbra, Inc.$2,000Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionCHEETAH2022
2022-07-01PFIZER INC.$196Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-06-30Genentech, Inc.$1,500Research paymentCash or cash equivalentTNKase Biological, Metabolism & Primary CareTENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS2022
2022-06-29PFIZER INC.$14,971Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-06-23Medtronic, Inc.$4,262Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2022
2022-06-23Medtronic, Inc.$4,262Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2022
2022-06-23Saranas, Inc.$1,173Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-06-22Genetesis, Inc.$8,850Research paymentCash or cash equivalentACCMED2022
2022-06-22Saranas, Inc.$2,558Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-06-22Gilead Sciences, Inc.$2,138Research paymentCash or cash equivalentA Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib2022
2022-06-22Saranas, Inc.$100Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-06-16Penumbra, Inc.$690Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2022
2022-06-15Genentech, Inc.$15,857Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-06-15PFIZER INC.$6,039Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-06-15Genentech, Inc.$5,603Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-06-15Genentech, Inc.$2,040Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-05-26Penumbra, Inc.$3,131Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2022
2022-05-20Impulse Dynamics (USA) Inc.$1,750Research paymentCash or cash equivalentOPTIMIZER Device, Cardiovascular DevicePost Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy2022
2022-05-18Gilead Sciences, Inc.$963Research paymentCash or cash equivalentA Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib2022
2022-05-11Gilead Sciences, Inc.$7,680Research paymentCash or cash equivalentA Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib2022
2022-05-10Medtronic, Inc.$800Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2022
2022-05-10Medtronic, Inc.$800Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2022
2022-05-05Penumbra, Inc.$1,750Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2022
2022-05-05Abbott Laboratories$500Research paymentCash or cash equivalent Device, Cardiac Rhythm ManagementSafety and Effectiveness Trial for the Nanostim Leadless Pacemaker2022
2022-05-05Penumbra, Inc.$250Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2022
2022-05-04E.R. Squibb & Sons, L.L.C.$14,450Research paymentCash or cash equivalentA Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa In2022
2022-04-27Abbott Laboratories$3,340Research paymentCash or cash equivalent Device, Cardiac Rhythm ManagementSafety and Effectiveness Trial for the Nanostim Leadless Pacemaker2022
2022-04-26Saranas, Inc.$9,532Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-04-26Saranas, Inc.$5,316Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-04-21Octapharma USA, Inc.$1,200Research paymentCash or cash equivalentPANZYGA Biological, IMMUNOLOGYNGAM-122022
2022-04-14Penumbra, Inc.$13,053Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE-PE2022
2022-04-14PFIZER INC.$1,067Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-04-14Abbott Laboratories$1,000Research paymentCash or cash equivalent Device, Cardiac Rhythm ManagementSafety and Effectiveness Trial for the Nanostim Leadless Pacemaker2022
2022-04-14Medtronic, Inc.$180Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2022
2022-04-14Medtronic, Inc.$180Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2022
2022-03-24Medtronic, Inc.$1,478Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2022
2022-03-24Medtronic, Inc.$1,478Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2022
2022-03-23Gilead Sciences, Inc.$1,238Research paymentCash or cash equivalentA Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib2022
2022-03-23Penumbra, Inc.$828Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE2022
2022-03-23Penumbra, Inc.$696Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE2022
2022-03-23Penumbra, Inc.$552Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE2022
2022-03-23Penumbra, Inc.$483Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE2022
2022-03-23Penumbra, Inc.$395Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE2022
2022-03-23Penumbra, Inc.$103Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE2022
2022-03-23Penumbra, Inc.$96Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE2022
2022-03-23Penumbra, Inc.$48Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIKE2022
2022-03-16PFIZER INC.$8,963Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-03-15AngioDynamics, Inc.$12,333Long term medical supply or device loanIn-kind items and servicesNanoKnife Device, Oncology Surgery2022
2022-03-14Genetesis, Inc.$15,090Research paymentCash or cash equivalentACCMED2022
2022-03-13Genetesis, Inc.$16,910Research paymentCash or cash equivalentACCMED2022
2022-03-11Abbott Laboratories$2,000Research paymentCash or cash equivalentTHORATEC HEARTMATE 3 LVAS IMPLANT KIT Device, Heart FailureSupporting Patients Undergoing HIgh-Risk PCI Using a High-Flow Percutaneous Left Ventricular Support Device (SHIELD II)2022
2022-03-04Genentech, Inc.$5,000Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-03-04Genentech, Inc.$2,842Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-03-04Genentech, Inc.$1,500Research paymentCash or cash equivalentXeloda Drug, BioOncologyMYTACTIC TARGETING ACTIONABLE MUTATION STUDY IN CANCER US PIIA MULTICENTER NONRANDOMIZED OPEN LBL2022
2022-02-25PFIZER INC.$97,969Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-02-24Alexion Pharmaceuticals, Inc.$2,895Research paymentCash or cash equivalentKANUMA Biological, Rare DiseaseAn Observational Disease and Clinical Outcomes Registry of Patients with Lysosomal Acid Lipase (LAL) Deficiency2022
2022-02-09Abbott Laboratories$6,010Research paymentCash or cash equivalent Device, Cardiac Rhythm ManagementSafety and Effectiveness Trial for the Nanostim Leadless Pacemaker2022
2022-02-07Genetesis, Inc.$21,510Research paymentCash or cash equivalentACCMED2022
2022-02-04PFIZER INC.$145,723Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-02-04Philips North America LLC$4,000Research paymentCash or cash equivalent(V021) iFR Device, Medical DeviceReVEAL iFR2022
2022-02-04Philips North America LLC$2,400Research paymentCash or cash equivalent(V021) iFR Device, Medical DeviceReVEAL iFR2022
2022-02-04Philips North America LLC$1,050Research paymentCash or cash equivalent(V021) iFR Device, Medical DeviceReVEAL iFR2022
2022-02-04Abbott Laboratories$500Research paymentCash or cash equivalent Device, Cardiac Rhythm ManagementSafety and Effectiveness Trial for the Nanostim Leadless Pacemaker2022
2022-02-03Medtronic, Inc.$5,000Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2022
2022-02-03Medtronic, Inc.$5,000Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsSMART Trial2022
2022-02-02Medtronic, Inc.$4,121Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2022
2022-02-02Medtronic, Inc.$4,121Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsTAVR Low Risk2022
2022-02-02Medtronic, Inc.$300Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsOptimize Pro2022
2022-02-02Medtronic, Inc.$300Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsOptimize Pro2022
2022-01-19Saranas, Inc.$100Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-01-18Medtronic, Inc.$9,441Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2022
2022-01-18Medtronic, Inc.$9,441Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsCoreValve SURTAVI2022
2022-01-16Saranas, Inc.$50Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-01-11Abbott Laboratories$415Research paymentCash or cash equivalentABSORB GT1 Device, VascularA Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects2022
2022-01-08PFIZER INC.$31,324Research paymentCash or cash equivalentA PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNI2022
2022-01-06Saranas, Inc.$8,000Research paymentCash or cash equivalentSARANAS SAFE-MCS STUDY2022
2022-01-05Cochlear Americas$165Debt forgivenessCash or cash equivalentCochlear Device, Implantable hearing solution2022

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Wayne CountyDetroit city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Detroit, MI, county Wayne County, MI, state Michigan; placed by its city name.

MeasurePlace (city or town)
Detroit, MI
County
Wayne County, MI
State
Michigan
Population B01003638,5301,772,25910,077,761
Population, 2020 census P1639,1111,793,56110,077,331
Median age B0100235.237.940.2
Under 18 B0100124.8%23.6%21.2%
65 and over B0100115.1%16.6%18.6%
Households B11001257,998700,5914,076,369
Foreign born B050026.6%10.3%7.2%
Median household income B19013$39,938$60,539$72,875
Median family income B19113$49,398$79,522$93,357
Per capita income B19301$24,594$34,906$40,735
Poverty rate B1700132.7%20.8%13.2%
Unemployment rate B2302514.0%8.7%5.7%
Civilian labor force B23025268,955828,8385,018,449
Mean commute (minutes) B0801324.824.724.2
Bachelor's degree or higher B1500318.1%27.6%32.4%
Housing units B25001329,393801,0834,622,236
Owner-occupied B2500350.3%64.8%73.2%
Renters B2500349.7%35.2%26.8%
Median home value B25077$83,900$178,500$231,600
Median gross rent B25064$1,074$1,132$1,129
White, not Hispanic B0300210.8%47.9%72.4%
Black B0300275.0%36.6%13.1%
Hispanic or Latino B030028.3%6.9%5.9%
Asian B030021.7%3.7%3.4%
American Indian and Alaska Native B030020.2%0.2%0.3%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Detroit, MI.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.